PALANDRI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 388
EU - Europa 207
AS - Asia 98
AF - Africa 1
Totale 694
Nazione #
US - Stati Uniti d'America 387
IE - Irlanda 58
SE - Svezia 55
HK - Hong Kong 51
IT - Italia 44
CN - Cina 27
RU - Federazione Russa 15
DE - Germania 10
CH - Svizzera 9
JO - Giordania 8
SG - Singapore 8
GB - Regno Unito 7
UA - Ucraina 5
FI - Finlandia 4
TR - Turchia 4
CA - Canada 1
SC - Seychelles 1
Totale 694
Città #
Chandler 78
Dublin 58
Ashburn 50
Hong Kong 34
Altamura 24
Lawrence 24
Fairfield 18
Moscow 15
Princeton 14
Shanghai 13
Beijing 12
Cambridge 12
Seattle 12
Boston 11
Wilmington 10
Bern 9
Jacksonville 9
San Diego 9
Woodbridge 9
Boardman 8
Medford 8
Washington 8
Buffalo 7
Houston 6
Singapore 5
Andover 4
Izmir 4
Ann Arbor 3
Bremen 3
Brugherio 3
London 3
Hangzhou 2
Kent 2
Norwalk 2
Pistoia 2
Rome 2
San Mateo 2
Arnsberg 1
Chicago 1
Falls Church 1
Florence 1
Fontevivo 1
Genoa 1
Hillsboro 1
Lappeenranta 1
New Bedfont 1
Redmond 1
Reston 1
Toronto 1
Treviso 1
Trumbull 1
West Jordan 1
Totale 510
Nome #
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 74
A modified adenine chemically coupled to the allergen molecule of Dermatophagoides pteronyssinus redirects allergen-specific Th2 cells 61
Total serum IgE levels influence the in vitro detection of ss-lactams-specific IgE antibodies 58
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 57
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 42
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey 41
A modified adenine chemically coupled to allergen molecule(s) induce Interferon-gamma production and down regulate IL-4 and IL-5 in Th2 specific T cells 40
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 40
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 39
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis 38
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 37
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 33
Long-term follow-up of recovered MPN patients with COVID-19 30
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 28
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study 19
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis 15
null 15
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis 13
Breakthrough infections in MPN-COVID vaccinated patients 13
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 12
Incidence of blast phase in myelofibrosis according to anemia severity 8
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 1
Totale 714
Categoria #
all - tutte 4.030
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.030


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202048 0 1 0 1 5 5 4 8 5 7 7 5
2020/202147 3 2 4 3 3 5 0 10 4 6 4 3
2021/202278 3 1 3 1 0 3 0 23 3 1 10 30
2022/2023319 24 73 20 17 23 45 32 21 38 6 8 12
2023/2024201 5 14 25 18 21 32 7 44 3 14 3 15
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 714